美国食品和药物管理局批准了辉瑞公司的一款治疗罕见出血性疾病的药物，该药物名为Hympavzi，通过自动注射器笔在皮肤下注射，以预防或减少12岁及以上血友病A或B患者的出血事件。

　　Hympavzi是辉瑞公司今年第二个获得美国食品药品监督管理局批准的血友病治疗药物，此前该机构于4月批准了其血友病B基因治疗Beqvez。

　　根据LSEG的估计，分析师预计到2030年，Hympavzi的销售额将达到3亿美元。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：陈钰嘉

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.